Coca-Cola and Johnson & Johnson sustain dividend growth with distinct strategies in 2026.

Coca-Cola closed 2025 with steady organic growth driven by its Zero Sugar beverages and announced a 63rd consecutive dividend increase. Despite a $960 million impairment on BODYARMOR and some regional volume declines, the company expects 4%-5% organic revenue growth in 2026. Johnson & Johnson started 2026 strong with accelerating pharmaceutical sales, especially in oncology, and maintained its 64-year dividend streak. It faces challenges from biosimilar competition but raised its revenue guidance to over $100 billion for 2026. Both companies are Dividend Kings but differ fundamentally: Coca-Cola focuses on stable consumer staples with low volatility, while Johnson & Johnson pursues growth through innovation and pipeline expansion. Investors should watch Coca-Cola’s global Zero Sugar momentum and Johnson & Johnson’s ability to offset biosimilar losses with new drug growth and business restructuring.